Boston Scientific reports positive data from long coronary lesions trial Equities.com Oct 26, 2012 (Datamonitor via COMTEX) -- Boston Scientific Corporation has reported clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the PROMUS Element Everolimus-Eluting Platinum Chromium, or PtCr, ... |
